We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.57%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$86.2B
AUM Growth
-$3.13B
(-3.5%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
0.26%
Top 10 Holdings %
Top 10 Hldgs %
24.96%
Holding
4,488
New
66
Increased
2,157
Reduced
1,702
Closed
141
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kenvue
KVUE
|
+$72.5M |
| 2 |
iShares Russell 1000 ETF
IWB
|
+$54.4M |
| 3 |
Blackstone
BX
|
+$44M |
| 4 |
Airbnb
ABNB
|
+$37.4M |
| 5 |
Everest Group
EG
|
+$30.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$57.8M |
| 2 |
LSI
Life Storage, Inc.
LSI
|
+$39.6M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$23.8M |
| 4 |
iShares Global Infrastructure ETF
IGF
|
+$19.2M |
| 5 |
PDCE
PDC Energy, Inc.
PDCE
|
+$18.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.73% |
| 2 | Healthcare | 12.76% |
| 3 | Financials | 12.67% |
| 4 | Consumer Discretionary | 11.16% |
| 5 | Industrials | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2226
Arcturus Therapeutics
ARCT
$211M
| $931K | ﹤0.01% |
36,437
+675
| +2% | +$20.8K |
|
2227
Viridian Therapeutics
VRDN
$2.67B
| $928K | ﹤0.01% |
60,497
+1,015
| +2% | +$19.4K |
|
2228
Ardmore Shipping
ASC
$683M
| $927K | ﹤0.01% |
71,270
-204
| -0.3% | -$2.63K |
|
2229
Douglas Dynamics
PLOW
$1.02B
| $927K | ﹤0.01% |
30,714
+65
| +0.2% | +$1.99K |
|
2230
Vitesse Energy
VTS
$665M
| $923K | ﹤0.01% |
40,314
+2,299
| +6% | +$54K |
|
2231
Transcat
TRNS
$871M
| $922K | ﹤0.01% |
9,414
+417
| +5% | +$39.9K |
|
|
CMRC
2232
Commerce.com Inc Series 1
CMRC
$184M
| $921K | ﹤0.01% |
93,321
-120
| -0.1% | -$1.25K |
|
2233
Portillo's
PTLO
$321M
| $920K | ﹤0.01% |
59,767
+6,303
| +12% | +$123K |
|
|
PKST
2234
DELISTED
Peakstone Realty Trust
PKST
| $916K | ﹤0.01% |
55,076
+12,720
| +30% | +$270K |
|
|
HDSN
2235
Hudson Technologies
HDSN
$235M
| $907K | ﹤0.01% |
68,227
-17
| -0% | -$183 |
|
2236
Ducommun
DCO
$2.98B
| $907K | ﹤0.01% |
20,837
+2,190
| +12% | +$99.4K |
|
|
GOLD
2237
Gold.com Inc
GOLD
$1.26B
| $902K | ﹤0.01% |
30,754
-27
| -0.1% | -$975 |
|
2238
Gray Television
GTN
$552M
| $900K | ﹤0.01% |
130,020
-665
| -0.5% | -$5.48K |
|
2239
Liberty Live Group Series A
LLYVA
$9.09B
| $900K | ﹤0.01% |
+28,185
| New | +$925K |
|
2240
Novavax
NVAX
$1.31B
| $899K | ﹤0.01% |
124,142
+834
| +0.7% | +$6.66K |
|
2241
Xometry
XMTR
$5.34B
| $898K | ﹤0.01% |
52,912
-399
| -0.7% | -$7.55K |
|
|
DHC
2242
Diversified Healthcare Trust
DHC
$2.14B
| $898K | ﹤0.01% |
462,651
-2,351
| -0.5% | -$5.96K |
|
2243
American Vanguard Corp
AVD
$68.9M
| $896K | ﹤0.01% |
82,015
-2,301
| -3% | -$35K |
|
|
INBX
2244
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $896K | ﹤0.01% |
48,825
-1,344
| -3% | -$28.1K |
|
2245
Takeda Pharmaceutical
TAK
$55.7B
| $896K | ﹤0.01% |
57,891
+575
| +1% | +$8.9K |
|
2246
Stoneridge
SRI
$213M
| $894K | ﹤0.01% |
44,530
-832
| -2% | -$16.9K |
|
2247
LSB Industries
LXU
$693M
| $891K | ﹤0.01% |
87,123
-1,089
| -1% | -$11.3K |
|
2248
Theravance Biopharma
TBPH
$877M
| $890K | ﹤0.01% |
103,166
-2,473
| -2% | -$23.9K |
|
|
OLO
2249
DELISTED
Olo Inc
OLO
| $889K | ﹤0.01% |
146,704
-972
| -0.7% | -$6.35K |
|
|
BF
2250
DELISTED
BASF AKTIENGESELLT ADS(RP1 ORD
BF
| $889K | ﹤0.01% |
78,772
-4,565
| -5% | -$51.5K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, RhumbLine Advisers held 4,488 positions worth $86.2B, down 3.5% from $89.3B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.6%. RhumbLine Advisers opened 66 new positions and exited 141, leaving the 4,488-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Financials.
- RhumbLine Advisers's largest Q3 2023 buy was Kenvue: 3,131,012 shares worth $62.9M.
- RhumbLine Advisers added most to iShares Russell 1000 ETF in Q3 2023, an estimated $54.4M increase.
- RhumbLine Advisers's biggest Q3 2023 reduction was Johnson & Johnson, cutting an estimated $57.8M.
- RhumbLine Advisers fully exited Life Storage, Inc. in Q3 2023, selling an estimated $39.6M.
- RhumbLine Advisers's ten largest holdings make up 25% of its $86.2B portfolio in Q3 2023.
- RhumbLine Advisers opened 66 new positions and closed 141 in Q3 2023.
- RhumbLine Advisers's portfolio value fell 3.5% quarter-over-quarter to $86.2B.
Based on RhumbLine Advisers's 13F filing for Q3 2023, filed 9 Nov 2023.